Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer

Inclusion Criteria: * Unresectable stage IIIA / IIIB non-small cell lung cancer with EGFR 19/21 mutation * No previous systemic anticancer therapy * Measurable lesion according to RECIST with at least one measurable lesion not previously irradiated, unless disease progression has been documented at that site * ECOG Performance Status of 0 to 1 Exclusion Criteria: * Prior treatment with anti-EGFR (the epidermal growth factor receptor) monoclonal antibody or small molecular compounds therapy such as gefitinib, erlotinib or cetuximab * Evidence of clinically active Interstitial Lung Diseases (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded) * Known severe hypersensitivity to icotinib or any of the excipients of this product